Cogent Capital Lease Obligations from 2010 to 2024
| COGT Stock | USD 9.58 0.05 0.52% |
Capital Lease Obligations | First Reported 2019-09-30 | Previous Quarter 18.5 M | Current Value 18.2 M | Quarterly Volatility 8.1 M |
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 36.1 M, as well as many indicators such as Price To Sales Ratio of 12.32, Dividend Yield of 0.0 or PTB Ratio of 1.23. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
Cogent | Capital Lease Obligations |
Latest Cogent Biosciences' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Cogent Biosciences over the last few years. Cogent Biosciences capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Cogent Biosciences asset purchases. For example, Cogent Biosciences can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Cogent Biosciences control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Cogent Biosciences' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Cogent Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 7,921,408 | |
| Geometric Mean | 6,976,717 | |
| Coefficient Of Variation | 61.90 | |
| Mean Deviation | 3,516,653 | |
| Median | 6,032,000 | |
| Standard Deviation | 4,903,555 | |
| Sample Variance | 24T | |
| Range | 16.5M | |
| R-Value | 0.55 | |
| Mean Square Error | 17.9T | |
| R-Squared | 0.31 | |
| Significance | 0.03 | |
| Slope | 608,085 | |
| Total Sum of Squares | 336.6T |
Cogent Capital Lease Obligations History
About Cogent Biosciences Financial Statements
Cogent Biosciences shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 18.9 M | 11.6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.